Baxter International Inc (BAX) is overvalued and we do not publish a verdict for Medline Inc (MDLN).
We publish an intrinsic value for BAX but not for MDLN, so the two cannot be ranked on price.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 7.3% values the shares at $8.41; the price of $23.68 is 182% above that value, and 81% of that value comes from beyond year five.
Leak Score 0/100 on 2 of 12 signals
We do not publish a value for this company: it has no growth history of its own to project.
Leak Score 29/100 on 5 of 12 signals
| Metric | BAX | MDLN |
|---|---|---|
| Verdict | Overvalued | Not valued |
| Price | $23.68 | $34.43 |
| Intrinsic value | $8.41 | — |
| Margin of safety | -182% | — |
| Leak Score | 0/100 (2/12) | 29/100 (5/12) |
| Market cap | $12.2B | $45.3B |
| Revenue growth, 5 years | -0.8% | — |
| Operating margin | 5.6% | 6.5% |
| Net margin | -8.6% | 2.3% |
| Return on equity | -14.3% | 4.9% |
| Debt to equity | 1.43 | 1.09 |
| P/E | — | 40.4x |
| Forward P/E | 11.6x | 21.8x |
| P/B | 2.0x | 2.6x |
| Dividend yield | 0.2% | 0.1% |